Synergistic interaction between oxaliplatin and SN-38 in human gastric cancer cell lines in vitro

Risa Tanaka, hiroshi ariyama, Baoli Qin, Yoshihiro Shibata, Yasushi Takii, Hitoshi Kusaba, Eishi Baba, Kenji Mitsugi, Mine Harada, Shuji Nakano

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

The interaction between CPT-11 and oxaliplatin, a new platinum derivative that has a great antitumor activity against colon cancer, has not been determined in gastric cancer cells. In this study, we investigated in vitro cytotoxic activity of oxaliplatin alone or in combination with SN-38, an active metabolite of CPT-11, using different exposure schedules in three human gastric cancer cell lines (AZ-521, MKN-45, and NUGC-4). Cytotoxicity was determined by WST-1 assay. Different treatment schedules of the two drugs were compared and evaluated for synergism, additivity, or antagonism with a quantitative method based on the median-effect principle of Chou and Talalay. Cell cycle perturbation was evaluated by flow cytometry. In 24-h exposure, simultaneous administration of oxaliplatin and SN-38 showed a synergistic effect in AZ-521 and NUGC-4 cells, and an additive effect in MKN-45 cells. Greater than additive effects were observed in all of the cell lines when cells were treated with oxaliplatin followed by SN-38, whereas such effects were observed only in NUGC-4 cells in the reverse sequence. Flow cytometric analyses at IC50 indicated that apoptosis was most prominent in simultaneous exposures with accumulation of cells in both G0/G1 and S phases. These results suggest that SN-38 may kill the cells recovering from the G1 block produced by oxaliplatin as they progress into the S phase. Simultaneous administration appears most active in gastric cancer cell lines. These results may provide important information for a clinical trial of oxaliplatin and CPT-11 combination for patients with gastric cancer.

Original languageEnglish
Pages (from-to)683-688
Number of pages6
JournalOncology Reports
Volume14
Issue number3
Publication statusPublished - Sep 1 2005

Fingerprint

irinotecan
oxaliplatin
Stomach Neoplasms
Cell Line
S Phase
Appointments and Schedules
Cell Cycle Resting Phase
G1 Phase
In Vitro Techniques
Platinum
Colonic Neoplasms
Inhibitory Concentration 50

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

Synergistic interaction between oxaliplatin and SN-38 in human gastric cancer cell lines in vitro. / Tanaka, Risa; ariyama, hiroshi; Qin, Baoli; Shibata, Yoshihiro; Takii, Yasushi; Kusaba, Hitoshi; Baba, Eishi; Mitsugi, Kenji; Harada, Mine; Nakano, Shuji.

In: Oncology Reports, Vol. 14, No. 3, 01.09.2005, p. 683-688.

Research output: Contribution to journalArticle

Tanaka, R, ariyama, H, Qin, B, Shibata, Y, Takii, Y, Kusaba, H, Baba, E, Mitsugi, K, Harada, M & Nakano, S 2005, 'Synergistic interaction between oxaliplatin and SN-38 in human gastric cancer cell lines in vitro', Oncology Reports, vol. 14, no. 3, pp. 683-688.
Tanaka, Risa ; ariyama, hiroshi ; Qin, Baoli ; Shibata, Yoshihiro ; Takii, Yasushi ; Kusaba, Hitoshi ; Baba, Eishi ; Mitsugi, Kenji ; Harada, Mine ; Nakano, Shuji. / Synergistic interaction between oxaliplatin and SN-38 in human gastric cancer cell lines in vitro. In: Oncology Reports. 2005 ; Vol. 14, No. 3. pp. 683-688.
@article{a5c62347121647168920d6677b1adebf,
title = "Synergistic interaction between oxaliplatin and SN-38 in human gastric cancer cell lines in vitro",
abstract = "The interaction between CPT-11 and oxaliplatin, a new platinum derivative that has a great antitumor activity against colon cancer, has not been determined in gastric cancer cells. In this study, we investigated in vitro cytotoxic activity of oxaliplatin alone or in combination with SN-38, an active metabolite of CPT-11, using different exposure schedules in three human gastric cancer cell lines (AZ-521, MKN-45, and NUGC-4). Cytotoxicity was determined by WST-1 assay. Different treatment schedules of the two drugs were compared and evaluated for synergism, additivity, or antagonism with a quantitative method based on the median-effect principle of Chou and Talalay. Cell cycle perturbation was evaluated by flow cytometry. In 24-h exposure, simultaneous administration of oxaliplatin and SN-38 showed a synergistic effect in AZ-521 and NUGC-4 cells, and an additive effect in MKN-45 cells. Greater than additive effects were observed in all of the cell lines when cells were treated with oxaliplatin followed by SN-38, whereas such effects were observed only in NUGC-4 cells in the reverse sequence. Flow cytometric analyses at IC50 indicated that apoptosis was most prominent in simultaneous exposures with accumulation of cells in both G0/G1 and S phases. These results suggest that SN-38 may kill the cells recovering from the G1 block produced by oxaliplatin as they progress into the S phase. Simultaneous administration appears most active in gastric cancer cell lines. These results may provide important information for a clinical trial of oxaliplatin and CPT-11 combination for patients with gastric cancer.",
author = "Risa Tanaka and hiroshi ariyama and Baoli Qin and Yoshihiro Shibata and Yasushi Takii and Hitoshi Kusaba and Eishi Baba and Kenji Mitsugi and Mine Harada and Shuji Nakano",
year = "2005",
month = "9",
day = "1",
language = "English",
volume = "14",
pages = "683--688",
journal = "Oncology Reports",
issn = "1021-335X",
publisher = "Spandidos Publications",
number = "3",

}

TY - JOUR

T1 - Synergistic interaction between oxaliplatin and SN-38 in human gastric cancer cell lines in vitro

AU - Tanaka, Risa

AU - ariyama, hiroshi

AU - Qin, Baoli

AU - Shibata, Yoshihiro

AU - Takii, Yasushi

AU - Kusaba, Hitoshi

AU - Baba, Eishi

AU - Mitsugi, Kenji

AU - Harada, Mine

AU - Nakano, Shuji

PY - 2005/9/1

Y1 - 2005/9/1

N2 - The interaction between CPT-11 and oxaliplatin, a new platinum derivative that has a great antitumor activity against colon cancer, has not been determined in gastric cancer cells. In this study, we investigated in vitro cytotoxic activity of oxaliplatin alone or in combination with SN-38, an active metabolite of CPT-11, using different exposure schedules in three human gastric cancer cell lines (AZ-521, MKN-45, and NUGC-4). Cytotoxicity was determined by WST-1 assay. Different treatment schedules of the two drugs were compared and evaluated for synergism, additivity, or antagonism with a quantitative method based on the median-effect principle of Chou and Talalay. Cell cycle perturbation was evaluated by flow cytometry. In 24-h exposure, simultaneous administration of oxaliplatin and SN-38 showed a synergistic effect in AZ-521 and NUGC-4 cells, and an additive effect in MKN-45 cells. Greater than additive effects were observed in all of the cell lines when cells were treated with oxaliplatin followed by SN-38, whereas such effects were observed only in NUGC-4 cells in the reverse sequence. Flow cytometric analyses at IC50 indicated that apoptosis was most prominent in simultaneous exposures with accumulation of cells in both G0/G1 and S phases. These results suggest that SN-38 may kill the cells recovering from the G1 block produced by oxaliplatin as they progress into the S phase. Simultaneous administration appears most active in gastric cancer cell lines. These results may provide important information for a clinical trial of oxaliplatin and CPT-11 combination for patients with gastric cancer.

AB - The interaction between CPT-11 and oxaliplatin, a new platinum derivative that has a great antitumor activity against colon cancer, has not been determined in gastric cancer cells. In this study, we investigated in vitro cytotoxic activity of oxaliplatin alone or in combination with SN-38, an active metabolite of CPT-11, using different exposure schedules in three human gastric cancer cell lines (AZ-521, MKN-45, and NUGC-4). Cytotoxicity was determined by WST-1 assay. Different treatment schedules of the two drugs were compared and evaluated for synergism, additivity, or antagonism with a quantitative method based on the median-effect principle of Chou and Talalay. Cell cycle perturbation was evaluated by flow cytometry. In 24-h exposure, simultaneous administration of oxaliplatin and SN-38 showed a synergistic effect in AZ-521 and NUGC-4 cells, and an additive effect in MKN-45 cells. Greater than additive effects were observed in all of the cell lines when cells were treated with oxaliplatin followed by SN-38, whereas such effects were observed only in NUGC-4 cells in the reverse sequence. Flow cytometric analyses at IC50 indicated that apoptosis was most prominent in simultaneous exposures with accumulation of cells in both G0/G1 and S phases. These results suggest that SN-38 may kill the cells recovering from the G1 block produced by oxaliplatin as they progress into the S phase. Simultaneous administration appears most active in gastric cancer cell lines. These results may provide important information for a clinical trial of oxaliplatin and CPT-11 combination for patients with gastric cancer.

UR - http://www.scopus.com/inward/record.url?scp=24644485386&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=24644485386&partnerID=8YFLogxK

M3 - Article

C2 - 16077975

AN - SCOPUS:24644485386

VL - 14

SP - 683

EP - 688

JO - Oncology Reports

JF - Oncology Reports

SN - 1021-335X

IS - 3

ER -